Seek Returns logo

ARGX vs. BNTX: A Head-to-Head Stock Comparison

Updated on

Here’s a clear look at ARGX and BNTX, comparing key factors like historical performance, profitability, financial strength, growth, dividend, and valuation.

Company Profile

Both ARGX and BNTX are American Depositary Receipts (ADRs). This provides U.S. investors with straightforward access to investing in these foreign-listed companies.

SymbolARGXBNTX
Company Nameargenx SEBioNTech SE
CountryNetherlandsGermany
GICS SectorHealth CareHealth Care
GICS IndustryBiotechnologyBiotechnology
Market Capitalization41.33 billion USD26.76 billion USD
ExchangeNasdaqGSNasdaqGS
Listing DateMay 18, 2017October 10, 2019
Security TypeADRADR

Historical Performance

This chart compares the performance of ARGX and BNTX by tracking the growth of an initial $10,000 investment in each. Use the tabs to select the desired time period. Data is adjusted for dividends and splits.

ARGX vs. BNTX: Growth of a $10,000 investment over the past one year.

Historical Performance at a Glance

SymbolARGXBNTX
5-Day Price Return1.49%-1.24%
13-Week Price Return7.13%13.80%
26-Week Price Return-8.03%-9.35%
52-Week Price Return20.32%23.76%
Month-to-Date Return-5.96%3.53%
Year-to-Date Return-6.83%-2.33%
10-Day Avg. Volume0.08M0.60M
3-Month Avg. Volume0.08M0.99M
3-Month Volatility36.77%45.29%
Beta0.751.53

Profitability

Return on Equity (TTM)

ARGX

17.59%

Biotechnology Industry

Max
77.14%
Q3
10.76%
Median
-20.08%
Q1
-42.71%
Min
-119.20%

In the upper quartile for the Biotechnology industry, ARGX’s Return on Equity of 17.59% signals a highly effective use of shareholder capital to drive profitability compared to most of its peers.

BNTX

-1.82%

Biotechnology Industry

Max
77.14%
Q3
10.76%
Median
-20.08%
Q1
-42.71%
Min
-119.20%

BNTX has a negative Return on Equity of -1.82%. This indicates the company is generating a loss for its shareholders, which can be a result of unprofitability or negative shareholder equity and is often a sign of financial distress.

ARGX vs. BNTX: A comparison of their Return on Equity (TTM) against the Biotechnology industry benchmark.

Net Profit Margin (TTM)

ARGX

-23.60%

Biotechnology Industry

Max
59.44%
Q3
16.21%
Median
-11.49%
Q1
-167.42%
Min
-409.07%

ARGX has a negative Net Profit Margin of -23.60%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

BNTX

-24.18%

Biotechnology Industry

Max
59.44%
Q3
16.21%
Median
-11.49%
Q1
-167.42%
Min
-409.07%

BNTX has a negative Net Profit Margin of -24.18%, indicating the company is operating at a net loss as its expenses exceeded its revenues.

ARGX vs. BNTX: A comparison of their Net Profit Margin (TTM) against the Biotechnology industry benchmark.

Operating Profit Margin (TTM)

ARGX

-40.34%

Biotechnology Industry

Max
60.62%
Q3
20.76%
Median
-12.41%
Q1
-181.14%
Min
-482.02%

ARGX has a negative Operating Profit Margin of -40.34%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

BNTX

-47.73%

Biotechnology Industry

Max
60.62%
Q3
20.76%
Median
-12.41%
Q1
-181.14%
Min
-482.02%

BNTX has a negative Operating Profit Margin of -47.73%. This signifies the company is unprofitable at the operational level, as its core business expenses exceed its revenue.

ARGX vs. BNTX: A comparison of their Operating Profit Margin (TTM) against the Biotechnology industry benchmark.

Profitability at a Glance

SymbolARGXBNTX
Return on Equity (TTM)17.59%-1.82%
Return on Assets (TTM)15.24%-1.57%
Net Profit Margin (TTM)-23.60%-24.18%
Operating Profit Margin (TTM)-40.34%-47.73%
Gross Profit Margin (TTM)90.83%84.90%

Financial Strength

Current Ratio (MRQ)

ARGX

5.60

Biotechnology Industry

Max
19.31
Q3
9.38
Median
4.54
Q1
2.45
Min
0.76

ARGX’s Current Ratio of 5.60 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

BNTX

8.61

Biotechnology Industry

Max
19.31
Q3
9.38
Median
4.54
Q1
2.45
Min
0.76

BNTX’s Current Ratio of 8.61 aligns with the median group of the Biotechnology industry, indicating that its short-term liquidity is in line with its sector peers.

ARGX vs. BNTX: A comparison of their Current Ratio (MRQ) against the Biotechnology industry benchmark.

Debt-to-Equity Ratio (MRQ)

ARGX

0.01

Biotechnology Industry

Max
1.35
Q3
0.64
Median
0.09
Q1
0.00
Min
0.00

ARGX’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

BNTX

0.01

Biotechnology Industry

Max
1.35
Q3
0.64
Median
0.09
Q1
0.00
Min
0.00

BNTX’s Debt-to-Equity Ratio of 0.01 is typical for the Biotechnology industry, indicating its use of leverage is in line with the sector norm. This suggests a balanced approach to its capital structure.

ARGX vs. BNTX: A comparison of their Debt-to-Equity Ratio (MRQ) against the Biotechnology industry benchmark.

Interest Coverage Ratio (TTM)

ARGX

-81.88

Biotechnology Industry

Max
72.37
Q3
1.91
Median
-7.81
Q1
-63.90
Min
-153.80

ARGX has a negative Interest Coverage Ratio of -81.88. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

BNTX

-1.43

Biotechnology Industry

Max
72.37
Q3
1.91
Median
-7.81
Q1
-63.90
Min
-153.80

BNTX has a negative Interest Coverage Ratio of -1.43. This indicates that its earnings were insufficient to cover even its operational costs, let alone its interest payments, signaling significant financial distress.

ARGX vs. BNTX: A comparison of their Interest Coverage Ratio (TTM) against the Biotechnology industry benchmark.

Financial Strength at a Glance

SymbolARGXBNTX
Current Ratio (MRQ)5.608.61
Quick Ratio (MRQ)4.928.48
Debt-to-Equity Ratio (MRQ)0.010.01
Interest Coverage Ratio (TTM)-81.88-1.43

Growth

Revenue Growth

ARGX vs. BNTX: A side-by-side comparison of their Revenue Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

EPS Growth

ARGX vs. BNTX: A side-by-side comparison of their EPS Growth for the MRQ (YoY), TTM (YoY), 3-Year CAGR, and 5-Year CAGR periods.

Dividend

Dividend Yield (TTM)

ARGX

0.00%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ARGX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

BNTX

0.00%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

BNTX currently does not pay a dividend, resulting in a yield of 0%. This is a common strategy for growth-focused companies that prioritize reinvesting earnings, though it may be less typical in mature, income-oriented sectors.

ARGX vs. BNTX: A comparison of their Dividend Yield (TTM) against the Biotechnology industry benchmark.

Dividend Payout Ratio (TTM)

ARGX

0.00%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

ARGX has a Dividend Payout Ratio of 0%, indicating it does not currently pay a dividend. This is a common strategy for growth-oriented companies that reinvest all profits back into the business.

BNTX

17.60%

Biotechnology Industry

Max
0.00%
Q3
0.00%
Median
0.00%
Q1
0.00%
Min
0.00%

At 17.60%, BNTX’s Dividend Payout Ratio is exceptionally high, exceeding the typical range for the Biotechnology industry. While this provides a significant return to shareholders, it may limit funds for reinvestment and could be difficult to sustain.

ARGX vs. BNTX: A comparison of their Dividend Payout Ratio (TTM) against the Biotechnology industry benchmark.

Dividend at a Glance

SymbolARGXBNTX
Dividend Yield (TTM)0.00%0.00%
Dividend Payout Ratio (TTM)0.00%17.60%

Valuation

Price-to-Earnings Ratio (TTM)

ARGX

31.14

Biotechnology Industry

Max
60.14
Q3
38.17
Median
29.01
Q1
15.12
Min
0.00

ARGX’s P/E Ratio of 31.14 is within the middle range for the Biotechnology industry. This suggests its valuation is in line with the sector average, representing neither a significant premium nor a discount compared to its peers.

BNTX

--

Biotechnology Industry

Max
60.14
Q3
38.17
Median
29.01
Q1
15.12
Min
0.00

P/E Ratio data for BNTX is currently unavailable.

ARGX vs. BNTX: A comparison of their Price-to-Earnings Ratio (TTM) against the Biotechnology industry benchmark.

Price-to-Sales Ratio (TTM)

ARGX

29.31

Biotechnology Industry

Max
76.98
Q3
36.53
Median
9.49
Q1
4.49
Min
0.00

ARGX’s P/S Ratio of 29.31 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

BNTX

8.35

Biotechnology Industry

Max
76.98
Q3
36.53
Median
9.49
Q1
4.49
Min
0.00

BNTX’s P/S Ratio of 8.35 aligns with the market consensus for the Biotechnology industry. This suggests its valuation, based on sales, is seen as standard and is on par with its competitors.

ARGX vs. BNTX: A comparison of their Price-to-Sales Ratio (TTM) against the Biotechnology industry benchmark.

Price-to-Book Ratio (MRQ)

ARGX

5.48

Biotechnology Industry

Max
20.53
Q3
9.76
Median
4.77
Q1
2.49
Min
0.59

ARGX’s P/B Ratio of 5.48 is within the conventional range for the Biotechnology industry. This shows a balanced market view, where the stock’s price is neither at a significant premium nor a discount to the book value of its peers.

BNTX

1.19

Biotechnology Industry

Max
20.53
Q3
9.76
Median
4.77
Q1
2.49
Min
0.59

BNTX’s P/B Ratio of 1.19 is in the lower quartile for the Biotechnology industry. From a value investing perspective, this is favorable, as it suggests the stock is trading at a discount to its net asset value and may offer a greater margin of safety.

ARGX vs. BNTX: A comparison of their Price-to-Book Ratio (MRQ) against the Biotechnology industry benchmark.

Valuation at a Glance

SymbolARGXBNTX
Price-to-Earnings Ratio (TTM)31.14--
Price-to-Sales Ratio (TTM)29.318.35
Price-to-Book Ratio (MRQ)5.481.19
Price-to-Free Cash Flow Ratio (TTM)--196.39